Annual Cash & Cash Equivalents
$100.14 M
+$24.61 M+32.57%
December 31, 2023
Summary
- As of February 25, 2025, ELVN annual cash & cash equivalents is $100.14 million, with the most recent change of +$24.61 million (+32.57%) on December 31, 2023.
- During the last 3 years, ELVN annual cash & cash equivalents has fallen by -$30.22 million (-23.18%).
- ELVN annual cash & cash equivalents is now -23.18% below its all-time high of $130.37 million, reached on December 1, 2020.
Performance
ELVN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$100.62 M
+$3.75 M+3.87%
September 30, 2024
Summary
- As of February 25, 2025, ELVN quarterly cash and cash equivalents is $100.62 million, with the most recent change of +$3.75 million (+3.87%) on September 30, 2024.
- Over the past year, ELVN quarterly cash and cash equivalents has stayed the same.
- ELVN quarterly cash and cash equivalents is now -65.55% below its all-time high of $292.10 million, reached on March 31, 2023.
Performance
ELVN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ELVN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +32.6% | 0.0% |
| 3 y3 years | -23.2% | -65.5% |
| 5 y5 years | -23.2% | -65.5% |
ELVN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -9.0% | +32.6% | -65.5% | +36.3% |
| 5 y | 5-year | -23.2% | +32.6% | -65.5% | +36.3% |
| alltime | all time | -23.2% | +32.6% | -65.5% | +36.3% |
Enliven Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $100.62 M(+3.9%) |
| Jun 2024 | - | $96.87 M(-35.1%) |
| Mar 2024 | - | $149.16 M(+49.0%) |
| Dec 2023 | $100.14 M | $100.14 M(+35.6%) |
| Sep 2023 | - | $73.85 M(-41.3%) |
| Jun 2023 | - | $125.72 M(-57.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $292.10 M(+286.7%) |
| Dec 2022 | $75.54 M(-31.3%) | $75.54 M(-12.3%) |
| Sep 2022 | - | $86.16 M(-21.7%) |
| Dec 2021 | $110.02 M(-15.6%) | - |
| Dec 2021 | - | $110.02 M |
| Dec 2020 | $130.37 M | - |
FAQ
- What is Enliven Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Enliven Therapeutics?
- What is Enliven Therapeutics annual cash & cash equivalents year-on-year change?
- What is Enliven Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Enliven Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ELVN is $100.14 M
What is the all time high annual cash & cash equivalents for Enliven Therapeutics?
Enliven Therapeutics all-time high annual cash & cash equivalents is $130.37 M
What is Enliven Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ELVN annual cash & cash equivalents has changed by +$24.61 M (+32.57%)
What is Enliven Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ELVN is $100.62 M
What is the all time high quarterly cash and cash equivalents for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly cash and cash equivalents is $292.10 M
What is Enliven Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ELVN quarterly cash and cash equivalents has changed by $0.00 (0.00%)